
Ardent Health (ARDT) shares dropped 5.5% after the company reported weaker Q2 2026 sales and net income, alongside cutting its full-year 2026 earnings guidance. Despite the reduced outlook, Ardent continued share repurchases, and options market volatility suggests traders anticipate significant price movements. The investment narrative now focuses on stabilizing margins under the new CEO amidst ongoing challenges from reimbursement pressures and labor costs.
Simply Wall Street
Original source
next uk
Check live status on DownRightNow

